2. Angiotensin I1 was infused at 2, 6, 18 and 54 ng min-' kg-I into sodium-depleted dogs. Plasma angiotensin I1 and arterial pressure both rose and were related in a dose-response curve.
Introduction
Captopril, an inhibitor of angiotensin I-converting enzyme, has a potent hypotensive effect inhibiting Correspondence: Dr J. J. Morton, MRC Blood Pressure Unit, Western Infirmary, Glasgow GI1 6NT, Scotland, U.K. the conversion of the inactive decapeptide angiotensin I (ANG I) into the pressor octapeptide angiotensin I1 (ANG 11) (Rubin, Antonaccio & Horovitz, 1978) . In sodium-depleted dogs, the fall in blood pressure after captopril correlates with the fall in plasma ANG I1 concentration (Morton, Tree & Casals-Stenzel, 1980 ) and although it is likely that the second is, at least, partly responsible for the first, other mechanisms may also be involved. In particular, captopril has been shown to potentiate the effects of the vasodilator peptide bradykinin by inhibiting its breakdown by kininase I1 (Engel, Schaeffer, Gold & Rubin, 1972; Erdos, 1976; Rubin, Laffan, Kotler, O'Keefe, Demaio & Goldberg, 1978) . Other possibilities also exist (see the Discussion section).
The following experiments were performed in conscious dogs to examine whether the reduction of plasma ANG I1 concentration is the sole mechanism whereby captopril reduces arterial pressure. A preliminary account of the work has already been given .
Methods

Experiment 1
Seven male beagle dogs (weighing 12-17 kg) with previously prepared carotid loops were fed a diet of high sodium content (404 mmol/day per dog) for 4 days. On day 5 the conscious dogs were infused via a fine polyethylene catheter into a forelimb vein. An initial control infusion of glucose solution was given for 1 h. Immediately after this, captopril (SQ 14 225, Squibb) was infused in glucose solution at a rate of 6 mg h-' kg-' for 3 h . Blood samples were taken at the end of the control infusion period and at 30, 120 and 180 min during the infusion of captopril. Arterial pressure was measured continuously via the carotid loop. Blood was assayed in four of the seven dogs for ANG 1 (Waite, 1973) and in all seven dogs plasma was assayed for A N G I1 (Dusterdieck & McElwee, 197 1 ; Morton, Semple, Ledingham, Stuart, Tehrani, Garcia & McGarrity, 1977) , aldosterone (Fraser, Guest & Young, 1973) , active renin (Millar, Leckie, Morton, Jordan & Tree, 1980) , sodium and potassium.
Experiment 2
Seven dogs were studied. The dogs were previously depleted of sodium by intravenous injection of frusemide (5 mg/kg) followed by a low sodium diet (4 mmollday per dog) for 4 days. Two separate infusion studies were then performed in each dog, in random sequence, and with an interval of at least 10 days between each study.
In the first, a control infusion of glucose solution was given for 1 h, after which [IleSJANG I1 was infused at 2, 6, 18 and 54 ng min-I kg-' in glucose solution, each rate of infusion lasting for 30 min. Blood samples were taken from the carotid loop for A N G I1 assay at the end of the control infusion period and at the end of each A N G I1 infusion rate. Arterial pressure was measured continuously as in experiment 1. Changes in arterial pressure were then related to concurrent plasma A N G I1 concentrations at each infusion rate. The second infusion study was performed exactly as for the first, with the exception that captopril (6 mg h-I kg-I) was infused in the glucose solution both during the preinfusion and during the A N G I1 infusion periods. Again changes in blood pressure were related to plasma A N G I1 concentration at each infusion rate.
Because of a previous observation that A N G I1 measurements in sodiumdepleted dogs given captopril can be falsely elevated due to cross-reaction in the assay with A N G I, the A N G I1 extracts from one dog subjected to both infusion studies were examined for this by a chromatographic technique, as previously described (Morton, Casals-Stenzel, Lever, Millar, Riegger & Tree, 1970) and any interference corrected for as described by Atkinson, Morton, Brown, Davies, Fraser, Kelly, Leckie, Lever & Robertson (1 980).
Statislics
Measurements obtained from experiment 1 were tested for significant differences by the onetailed Wilcoxon matched-pairs signed-rank test. ANG II/blood pressure dose-response slopes obtained in experiment 2 were compared by a common-slope regression test ( F test) based on an analysis of variance, and differences in blood pressure and A N G I1 were compared by Student's t-test for paired observations. Mean results ? SD are shown.
Results
Experiment I
All dogs were in positive sodium balance before the infusion of captopril (mean cumulative balance during the 4 days of sodium loading was
Mean results of the infusion are shown in Fig ; ;
Effect of captopril (6 mg hk' kg-') in sodiumloaded dogs on plasma A N G 11. blood pressure. plasma aldosterone, blood ANG I, renin concentration, serum sodium and potassium. Bars are f I SEM.
Significance of differences from basal values: *P < 0.01: **P < 0.025. Blood A N G 1 measurements were not analysed as results from only four of the seven dogs were obtained.
end of the control period (11.0 f 3-0 pmol/l), and was further suppressed within 30 niin of starting the captopril infusion and remained suppressed throughout (1.6 f 1.3 pmol/l at 180 min). Mean arterial pressure also fell with captopril, the maximum mean fall for the group being 20.4 f 6.7 mmHg at 180 min. There was no correlation between the fall in blood pressure and the fall in plasma ANG I1 concentration.
Plasma aldosterone concentration fell with captopril (169 f 36 to 66.5 f 41.6 pmol/l at 180 min). There was a strong positive correlation, which was weakly significant between the fall in plasma ANG I1 and the fall in plasma aldosterone ( r = 0.8, P < 0.05). Both active renin and blood ANG I concentrations increased (15 f 7 to 83 f 58 p-units/ml and 6 f 2 to 30 f: 1 pmol/l respectively). Individual measurements of plasma ANG 11 and blood pressure for all seven dogs are given in Table 1 .
Experiment 2
Before this study all dogs were in negative sodium balance (mean cumulative balance for the 4 days being -42.7 f 4.2 mmol).
Individual plasma ANG I1 concentratioris and blood pressures for all seven dogs are given in Table 2 . There was no indication of any ANG I interference in the ANG I1 assay for samples from the dose-response study in the glucoseinfused dog. Only in the second study, after captopril infusion, was any ANG I interference detected and this was most evident in the tontrol samples. Plasma ANG I1 concentration during the control glucose infusion was 48.0 & 16.6 pmol/l whereas the uncorrected and corrected values after the captopril control infusion were 9.0 f 3.0 and 2.6 f 6.0 pmol/l respectively. There was a small amount of ANG I interference detected in two of the seven samples obtained after ANG I1 infusion at 2 ng min-I kg-' but the mean uncorrected and corrected values were very similar (20.5 and 19.0 pmol/l respectively). There was no interference at any of the other infusion rates presumably as a result of the infused A N G I1 suppressing renin and hence A N G I concentration.
The relationship between blood pressure and plasma A N G I1 concentration for both infusion studies is shown in Fig. 2 topril had to have a plasma A N G 11 concentration fivefold greater (240 as compared with 4 8 pmol/l). Morton & Robertson, 1979; Millar, Matthews, McGrath & Johnston, 1979) . However, it should be emphasized that results from studies with the A N G 11-receptor antagonist, saralasin, should be interpreted with caution owing to its residual agonist property. The fact that there was a fall in arterial pressure when captopril was infused into sodium-loaded dogs agrees with a similar observation in normal and salt-loaded man (MacGregor, Markandu, Roulston, Jones & Morton, 1980) , and could have two interpretations. Either increased pressor sensitivity in the sodium-loaded state results in the very low levels of A N G I1 being within the pressor range, and captopril lowers pressure (partly or wholly) by a further reduction in its concentration, or circulating A N G I1 is below the pressor range, in which case captopril lowers blood pressure by some other mechanisms. We have previously demonstrated, in sodium-depleted dogs, a correlation between the fall in blood pressure and the fall in plasma ANG I1 after infusion of captopril (Morton et af., 1980) suggesting that, under these conditions, suppression of plasma A N G I1 is involved in the hypotensive response. Our inability to demonstrate such a correlation in sodium-loaded dogs, while at the same time being able to show a correlation between the fall in ANG I1 and the fall in plasma aldosterone, suggests that factors other than A N G I1 may also be involved in the hypotensive effect. More conclusive evidence comes from the second experiment, in which captopril produced a downward shift in the A N G I1 blood pressure dose-response curve. This implies that diminution of the acute vasoconstrictor effect of A N G 11, consequent on a reduction of its plasma concentration, is not the sole mechanism lowering arterial pressure. A number of alternative possibilities exist. Arterial pressure may be partly controlled by A N G 11 generated, both in the circulation and within the blood vessel wall (Oparil, Koerner and O'Donoghue, 1979; Swales, 1979; Thurston, Swales, Bing, Hurst & Marks, 1980) . If captopril inhibited the formation of both, then infusion of ANG I1 into the circulation would only partly restore blood pressure to normal. A second possibility is that captopril potentiates the effect of the vasodilator peptide, bradykinin, by inhibiting kininase 11, the enzyme responsible for its breakdown and synonymous with angiotensinconverting enzyme (Erdos, 1976) . The evidence for this is unclear and often conflicting (Williams & Hollenberg, 1977; Hulthen & Hokfelt, 1978; Johnston, Millar, McGrath & Matthews, 1979) but it remains a distinct possibility. A third possibility is that prostaglandins are involved in the fall of blood pressure, as suggested by the ability of indomethacin to impair the hypotensive effect of captopril (Dollery & Miyamori, 1980) . Finally, prolonged infusion of ANG I1 in low dose raises blood pressure gradually in the dog (Bean, Brown, Casals-Stenzel, Fraser, Lever, Millar, Morton & Petch, 1979) and shifts the ANG II/blood pressure dose-response curve upwards. If endogenous ANG I1 in plasma contributed towards this effect, and if the effect is reversed by captopril, infusion of exogenous ANG I1 during captopril would result in a downward shift in the dose-response curve.
Thus captopril appears to lower blood pressure acutely, partly by reducing the plasma concentration of ANG I1 and partly by some other mechanism(s). Using different techniques (infusion of captopril in the presence of other antagonists), Marks, Bing, Thurston & Swales (1980) reach a similar conclusion, as do Swartz, Williams, Hollenberg, Moore & Dluhy, (1979) using another converting-enzyme inhibitor. The drug also lowers blood pressure in the long term and the mechanism here may be different (Bengis, Coleman, Young & McCaa, 1978; McCaa, Hall & McCaa, 1978; Johnston et al., 1979) .
